I don't see PolyMedix being a factor in this for many years, if ever. They've had enough trouble just getting Brilacidin into P2b testing for ABSSSI and even after a RS and massive dilution will not likely have a hope to obtain funding to advance development of other drugs or even the same drug for different diseases anytime soon (if ever).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.